| Objective: To observe the efficacy and safety of traditional Chinese medicine Bufei Huoxue Decoction on the basis of conventional western medicine treatment in the treatment of patients with chronic pulmonary heart disease caused by chronic obstructive pulmonary disease(COPD)with Qi deficiency and blood stasis syndrome in remission period.To explore its clinical value and promotion significance for chronic pulmonary heart disease in remission.Methods: A total of 68 patients aged 45-80 who met the diagnostic criteria for chronic pulmonary heart disease in remission(Qi deficiency and blood stasis syndrome)were divided into an experimental group of 34 cases and a control group of 34 cases according to the randomized and controlled clinical trial design method.In practice,1 case in the experimental group was discontinued,and 1 case in the control group dropped out.The control group was given conventional western medicine treatment(general basic treatment;budesonide formoterol powder inhalation 320/9.0 μg/inhalation,once in the morning and evening;tiotropium bromide powder inhalation 18 μg/inhalation,once a day;and as appropriate Give cough,diuretic,anti-infective treatment).On the basis of the treatment method of the control group,the experimental group simultaneously took the modified formula of Bufei Huoxue decoction prepared by the Chinese Pharmacy of Zhangzhou Hospital of Traditional Chinese Medicine.After 12 weeks of treatment,the changes of TCM syndrome scores,FEV1/FVC,PASP,D-Dimer,6MWT and other indicators in the two groups were observed,and the average daily oxygen inhalation time,hospitalization times,hospitalization days and expenses were recorded during the 6-month follow-up.Results:(1)There was no statistical difference between the two groups in gender distribution,age,course of disease,BMI,lung function classification and other baseline comparisons(P>0.05),which were comparable.(2)Evaluation of clinical efficacy: the total effective rate of the experimental group was93.94%,and the total effective rate of the control group was 75.76%.After statistical analysis,there was a difference in the total effective rate between the two groups(P<0.01),indicating that the experimental group could improve the patients more effectively.Clinical symptoms.(3)Symptom score evaluation: Compared with the total symptom score before and after treatment,both groups could improve the patient’s symptom score(P<0.01),and the overall score of the experimental group was lower than that of the control group after treatment(P<0.01).Comparing the two groups before and after treatment,all symptoms after treatment were significantly improved(P < 0.01).There were no significant differences in 6 aspects including defecation weakness(P>0.05);in expectoration,wheezing,shortness of breath,spontaneous sweating and fear of wind,the differences were statistically significant(P<0.05).(4)Evaluation of laboratory indicators: After treatment,FEV1/FVC in both groups increased(P<0.01),and compared between groups,the experimental group was significantly better than the control group(P<0.01).Compared with the control group,the experimental group was significantly better than the control group(P<0.01);after treatment,the D-Dimer of the two groups decreased(P<0.01).better than the control group(P < 0.01);after treatment,the6 MWT of both groups increased(P < 0.01).Compared between the groups,the experimental group was significantly better than the control group(P < 0.01).(5)During the 6-month follow-up after treatment,the average daily home oxygen inhalation time,hospitalization times,hospitalization days and expenses were compared between the two groups,and the differences were statistically significant(P<0.05).The frequency,days of hospitalization and expenses were lower than those of the control group.(6)Safety evaluation: During the treatment process of the two groups,there were no obvious abnormalities in relevant safety indicators such as body temperature,respiration,heart rate,blood pressure,routine blood,urine and feces,liver and kidney function,and electrocardiogram.Conclusion: Bufei Huoxue Decoction in the treatment of patients with chronic pulmonary heart disease in remission has a good effect in improving symptoms,improving quality of life,improving cardiopulmonary function,and reducing the number of hospitalizations,days,and costs,and can improve blood coagulation indexes and safety performance.Reliable and worthy of clinical promotion. |
PDF Full Text Request